Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension <scp>JADE EXTEND</scp> study
Kristian Reich(Dermatologikum Hamburg), Claire Clibborn(Pfizer (United Kingdom)), Kim Papp(University of Toronto), Jonathan I. Silverberg(George Washington University), Marjolein de Bruin‐Weller(Netherlands Center for Occupational Diseases), Thomas Werfel(Medizinische Hochschule Hannover), Mette Deleuran(Aarhus University Hospital), F. Zhang(Pfizer (United States)), Norito Katoh(Kyoto Prefectural University of Medicine), Marco DiBonaventura(Kantar Health (United States)), U. Kerkmann(Pfizer (Germany)), Saleem A. Farooqui(Pfizer (United Kingdom)), Pinaki Biswas(Pfizer (United States)), Lisa A. Beck(University of Rochester Medicine), Bruce Strober(Yale University), Gary Chan(Khoo Teck Puat Hospital)
Cited by 9
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k